IUPAC: 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine · C₁₇H₁₃ClN₄ · MW 308.77 g/mol · CAS 28981-97-7 · ATC N05BA12
Alprazolam (Xanax). A high-potency triazolobenzodiazepine — a 1,4-benzodiazepine fused to a triazole ring, synthesized at Upjohn (U-31,889) and approved in 1981. A positive allosteric modulator of the GABAA receptor at the benzodiazepine site, FDA-approved for panic disorder and generalized anxiety. Rapid onset, short half-life, no long-lived active metabolites — the pharmacokinetic opposite of diazepam, and the reason it is both the most-prescribed benzodiazepine and the one most associated with dependence and difficult withdrawal. Trade/context names: Xanax, Niravam, "bars," "zannies," "footballs."
Alprazolam does not open the chloride channel by itself. Like every classical benzodiazepine it is a positive allosteric modulator (PAM) that binds the extracellular pocket at the α+/γ2− subunit interface of the pentameric GABAA receptor — the "benzodiazepine site," structurally homologous to the two orthosteric GABA sites at the β+/α− interfaces. When GABA is present, alprazolam raises the receptor's affinity for GABA and increases the frequency of channel openings. It amplifies existing inhibition; it does not create it. That use-dependence is why isolated benzodiazepine overdose has a ceiling — and why the ceiling disappears the instant a second CNS depressant is added (see §04).
What distinguishes alprazolam is not the site but the scaffold. The triazolo ring fused across the 1,2-position of the diazepine core raises intrinsic affinity and potency well above diazepam (roughly an order of magnitude: 0.5 mg alprazolam is broadly equivalent to 5–10 mg diazepam), and gives it a steep, fast-rising concentration–effect curve. High potency plus fast onset plus short duration is precisely the profile that maximizes reinforcement and interdose rebound.
GABAA is a ligand-gated anion channel. GABA binding at the two β+/α− sites opens the pore; Cl⁻ (and HCO₃⁻) flows down its electrochemical gradient, hyperpolarizing the neuron and raising firing threshold. Alprazolam adds nothing without GABA — it is pure gain, not a switch.
The conserved α-subunit His-101 (α1 numbering) is required for high-affinity BZD binding. α4 and α6 carry an arginine at this position, making α4/α6-containing receptors "diazepam-insensitive." Alprazolam is captured at exactly this histidine-gated aromatic pocket, seen directly in the 6HUO cryo-EM structure at right.
α1βγ2 receptors (~60% of brain GABAA) carry sedation, anterograde amnesia, anticonvulsant action and much of the reinforcing, abuse-related effect. Alprazolam's high α1 efficacy plus fast onset is a large part of why it is the benzodiazepine most reported in non-medical use.
α2- and α3-containing receptors (limbic system, spinal cord) carry the anxiolytic and myorelaxant effects. Alprazolam is essentially non-selective across α1/α2/α3/α5 — which is why it is simultaneously anxiolytic, anti-panic, sedating, amnestic and reinforcing rather than a clean single-effect drug.
The fused [1,2,4]triazolo ring is the defining feature of the class (alprazolam, triazolam, midazolam, and the illicit designer analogs flualprazolam/bromazolam). It increases BZD-site affinity and confers the characteristically rapid, high-potency pharmacology — and, in the designer analogs, extreme potency at street doses.
Triazolobenzodiazepines are also weak platelet-activating-factor (PAF) receptor antagonists — a genuine off-target property historically invoked to explain some antidepressant/anti-panic signal, though it is not the driver of the anxiolytic effect, which is GABAergic.
Because the effect is use-dependent on ambient GABA, alprazolam in isolation has a self-limiting envelope: it can only amplify inhibition where GABA is already being released. Ethanol at high concentration, barbiturates, and — critically — the additive load of an opioid on the same brainstem respiratory circuitry remove that ceiling entirely.
Alprazolam is well absorbed orally (bioavailability ~80–90%), reaching peak plasma at 1–2 hours with a rapid, palpable onset. Its defining pharmacokinetic feature — and the mechanistic root of its clinical problems — is that it is short-acting with no long-lived active metabolites. The parent half-life is roughly 11–13 hours (the extended-release formulation flattens but does not lengthen the curve), and its two oxidative metabolites, 4-hydroxyalprazolam and α-hydroxyalprazolam, are only weakly active and quickly cleared. Contrast diazepam, whose nordazepam tail smooths concentrations over days: alprazolam gives a clean, sharp peak that then falls away — and the falling limb is where trouble starts.
Metabolism cascade: Alprazolam is oxidized almost entirely by CYP3A4 to 4-hydroxyalprazolam and α-hydroxyalprazolam, which are then glucuronidated and renally cleared. Both hydroxymetabolites are far less potent than the parent and short-lived, so — unlike diazepam — essentially all of the clinical effect is the parent drug itself. There is no self-refilling reservoir; when the parent falls, the effect falls with it.
Because clearance funnels through a single enzyme, CYP3A4 inhibitors — ketoconazole and other azoles, clarithromycin/erythromycin, ritonavir and other protease inhibitors, nefazodone, and grapefruit juice — sharply raise alprazolam exposure and can turn a routine dose into an over-sedating one. Conversely, CYP3A4 inducers (carbamazepine, rifampin, St John's wort) can drop levels and precipitate withdrawal.
The clinically decisive point is the mismatch between duration of action and dosing interval. A short half-life used two or three times daily for a chronic condition means plasma levels trough between doses. In a benzodiazepine-adapted brain, each trough is a miniature withdrawal — rebound anxiety, even panic, hours before the next dose is due. Patients (and the physiology) read this as "the anxiety is back, I need the pill," and the drug teaches its own escalation. This interdose-rebound loop is the engine behind alprazolam's outsized dependence reputation relative to longer-acting benzodiazepines.
Alprazolam is genuinely effective for panic disorder and acute anxiety: the fast onset that makes it reinforcing is the same property that aborts a panic attack in real time. That is its therapeutic appeal and its trap. The subjective effect — rapid anxiolysis, calm, mild euphoria and disinhibition (largely α1-mediated) — arrives quickly, peaks, and then recedes on the same timescale, and the GABAergic system responds to repeated sharp potentiation by remodeling itself. That remodeling is what produces tolerance, dependence, and a withdrawal syndrome that can be lethal.
By potentiating α2/α3 GABAA receptors across the amygdala and limbic circuitry, alprazolam rapidly dampens the runaway excitation of a panic attack. Its rapid absorption gives it a near-abortive quality that slower anxiolytics (SSRIs, buspirone) lack — which is exactly why it gets used "as needed," and why as-needed use so readily becomes scheduled dependence.
With chronic exposure, GABAA receptors undergo subunit trafficking and uncoupling of the BZD site from the GABA site. Sedative and anticonvulsant tolerance develop fastest; anxiolytic tolerance is slower and partial. The same dose delivers progressively less effect, and the short half-life makes the loss obvious between doses — a direct invitation to escalate.
To offset chronic inhibition, the CNS down-regulates GABAergic tone and up-regulates glutamatergic (NMDA) drive. While alprazolam is present the system is balanced; remove it and the compensations are unmasked — a brain now wired for hyperexcitability. Dependence can develop within weeks of daily therapeutic use, and alprazolam's short duration means the unmasking begins fast. This is physiology, not weakness.
Abrupt cessation after sustained use produces rebound anxiety and insomnia, tremor, sweating, perceptual disturbance and — in severe cases — generalized tonic-clonic seizures, psychosis and delirium, mechanistically analogous to alcohol withdrawal. Because alprazolam is short-acting, withdrawal can arrive within a day of the last dose and is often more abrupt and intense than with long-acting benzodiazepines. A subset experience protracted withdrawal lasting months.
The evidence-based response to discontinuation is a slow, gradual taper — never an abrupt stop after regular use. Because alprazolam's short half-life makes step-downs jagged, the standard maneuver (the "Ashton" approach) is often to cross-titrate onto a long-acting benzodiazepine such as diazepam, whose slow decline smooths the withdrawal gradient, and then reduce in small decrements over weeks to months. Taper is a medical procedure, not a test of willpower. This is the central asymmetry of alprazolam: in isolation it is one of the safer molecules ever made against fatal respiratory depression — yet it creates a dependence that makes stopping genuinely hazardous, and it becomes lethal the instant it is stacked with another respiratory depressant.
Evidence-based, non-judgmental. Alprazolam's danger is dominated by three things: what you combine it with, how you stop it, and what the pill actually contains. All three are manageable with accurate information.
| Target | Affinity | Rel. | Action |
|---|---|---|---|
|
GABAA · BZD site
[³H]flumazenil displacement
|
Ki ≈ 3.3 nM
ChEMBL CHEMBL661
|
PAM | |
|
α1βγ2
GABAA · sedation / amnesia
|
low-nM
non-selective
|
PAM | |
|
α2/α3βγ2
GABAA · anxiolytic / anti-panic
|
low-nM
non-selective
|
PAM | |
|
α5βγ2
GABAA · hippocampal / memory
|
low-nM
non-selective
|
PAM | |
|
α6βγ2
GABAA · "diazepam-insensitive"
|
µM-range
Arg at His-101
|
≈ inactive | |
|
PAF receptor
Platelet-activating factor R
|
weak
off-target
|
Antagonist |